SCHEMBL4258062

SCHEMBL4258062

CC(C)(C)OC(=O)/C=C(/Oc1cccc([N+](=O)[O-])c1)C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
F2 P00734 1/20 0.46
HGFAC Q04756 1/20 0.45
ALOX5 P09917 2/20 0.44
ALDH1A1 P00352 4/20 0.40
NR3C2 P08235 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HSP90AA1 P07900 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NLRP1 Q9C000 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251537 1.00 MAPT (0.46) MAPTNPC1RAB9ASMN1; SMN2F2
SCHEMBL4251542 1.00 MAPT (0.46) MAPTNPC1RAB9ASMN1; SMN2F2
SCHEMBL4253496 0.85 GAA (0.48) MAPTNPC1RAB9ASMN1; SMN2HGFAC
SCHEMBL4256047 0.85 GAA (0.48) MAPTNPC1RAB9ASMN1; SMN2HGFAC
SCHEMBL4253501 0.85 GAA (0.48) MAPTNPC1RAB9ASMN1; SMN2HGFAC
SCHEMBL4246726 0.81 ALDH1A1 (0.50) MAPTNPC1RAB9ASMN1; SMN2F2
SCHEMBL4246720 0.81 ALDH1A1 (0.50) MAPTNPC1RAB9ASMN1; SMN2F2
SCHEMBL4256581 0.81 ALDH1A1 (0.50) MAPTNPC1RAB9ASMN1; SMN2F2
SCHEMBL4253509 0.78 GLO1 (0.53) MAPTNPC1F2HGFACALOX5
SCHEMBL4256029 0.78 GLO1 (0.53) MAPTNPC1F2HGFACALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2105432-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-2105431-A1 Process for Producing Chromone Compound Sumitomo Chemical Company, Limited (JP) 2009-09-30 EP disclosed
EP-1867626-A2 Process for producing chromone compound Sumitomo Chemical Company, Limited (JP) 2007-12-19 EP disclosed
US-20060217565-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-28 US disclosed
US-7094914-B2 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-22 US disclosed
US-20050085664-A1 Process for producing chromone compound SUMITOMO CHEMICAL COMPANY, LMITED (JP) 2005-04-21 US disclosed
EP-1479667-A1 PROCESS FOR PRODUCING CHROMONE COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085664-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL MAPT 4765/4885NPC1 2630/4885RAB9A 3116/4885
US-20060217565-A1 Process for producing chromone compound ENY2, CDY1; CDY1B, CDYL MAPT 4765/4885NPC1 2630/4885RAB9A 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.